The treatment of lichen planus with topical roflumilast 0.3%

Abstract

Listen

Translate article

Lichen planus is a rare and chronic inflammatory skin disorder that imposes a high psychosocial burden on affected patients. Currently, no FDA-approved treatments exist for lichen planus, and it remains to be a therapeutic challenge for health care practitioners, especially in patients who are uninterested in trying topical corticosteroids or systemic therapies. We describe the reduction of erythema and resolution of pruritus following treatment with a once-daily nonsteroidal topical, roflumilast cream 0.3%, in a patient with lichen planus who had previously failed topical and intramuscular corticosteroid treatment.